Levonorgestrel-Releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer | MicrobiomeTrials
Levonorgestrel-Releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2015-09-23Est. Completion: 2028-09-30
Enrollment target: 102 participants
Locations
North Colorado Medical Center, Greeley, Colorado, United States
McKee Medical Center, Loveland, Colorado, United States
Queen's Medical Center, Honolulu, Hawaii, United States
Covenant HealthCare Mackinaw, Saginaw, Michigan, United States
Cooper Hospital University Medical Center, Camden, New Jersey, United States
MD Anderson Cancer Center at Cooper-Voorhees, Voorhees Township, New Jersey, United States
Northwell Health, New Hyde Park, New York, United States
OhioHealth Mansfield Hospital, Mansfield, Ohio, United States
University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
MD Anderson in The Woodlands, Conroe, Texas, United States
Memorial Hermann Memorial City Medical Center, Houston, Texas, United States
Lyndon Baines Johnson General Hospital, Houston, Texas, United States
M D Anderson Cancer Center, Houston, Texas, United States
The Woman's Hospital of Texas, Houston, Texas, United States
MD Anderson West Houston, Houston, Texas, United States
MD Anderson League City, League City, Texas, United States
Other microbiome trials you might be interested in